Background: Shortening the interval between cycles is one means of increasing the dose intensity of chemotherapy, and can be supported by biological and mathematical rationales. Our objective was to assess the clinical relevance of the rapid repetition of regimens (so-called 'dose-dense chemotherapy') in various solid neoplasms.
Introduction
Chemotherapy is used in a wide spectrum of neoplasms. Historically, the treatment schedule and timing of chemotherapy was dictated by neutrophil recovery kinetics. With most myelosuppressive agents used alone or in combination, peripheral granulocyte nadirs are reached in about 10-15 days and recovery is achieved in about 21 days [1] . Except in the case of nitrosoureas, these data have since been extensively substantiated. Bone marrow stem-cell proliferation is at a maximum when the granulocyte nadir is reached and recycling of chemotherapy at that point, and particularly of cycle-specific agents, may lead to considerable hematopoietic damage. It was decided that treatment intervals should be prolonged and, since the 1960s, it has been a rule of thumb to design most chemotherapy combinations to be repeated every three or four weeks. This applies to the bestknown regimens such as MOPP, CHOP, CMF, FAC and PVB. The interval was often fixed in weeks and not in days, for practical reasons. However, the possibilities of repeating therapy between the tenth and twenty-first days were not assessed.
More recently, certain authors have developed new theories derived from basic concepts of chemotherapy, to optimize the practical use of this anticancer tool. First, Goldie and Coldman hypothetized that the emergence of drug-resistant clones within tumours was genetically programmed [2] . They recommended the use of a dose-intensive strategy to circumvent cell mutations. Their theory was that this could be obtained by rapidly alternating the treatment plan to preclude dose-limiting toxicity, so that the intervals between cycles could be reduced. Both this theory and the classic log-kill model [3] were challenged by Norton and Simon [4] . These latter authors agreed that a rapid reduction of the tumor burden could best be achieved if the entire treatment was administered over as short a period as possible. They developed a mathematical kinetic model of the effective level of therapy to support these assumptions, later designated the Norton-Simon model. However, contrary to Goldie and Coldman, they recommended a sequential administration of chemotherapy instead of an alternated schedule. This theory was subsequently confirmed by a randomized Italian trial which found a remarkable advantage in a sequential as opposed to an alternating design of a regimen comprising doxorubicin and CMF in stage II breast cancer [5] . Both Goldie's and Norton's models outlined the short timing of recycling.
Shortening the interval between chemotherapy cycles could be achieved in a number of ways. Firstly, this could be done without additional therapies by administering full conventional doses or even higher doses after a short interval, whatever the granulocyte count at the time of recycling. This has been performed safely in advanced breast cancer [6] . Secondly, hematopoietic growth factors (HGF) can provide support. This strategy has been developed worldwide, but to date there is no evidence of an improvement in neutropenia-related mortality with the use of cytokines [7] . The third method consists in reinjecting autologous peripheral blood stem cells after some or all of the cycles. One of the major advantages of this approach is that not only is the time to granulocyte recovery reduced, but also that of platelets and red cells counts, compared to the HGF currently available [8] . Finally, the current and future development of chemoprotectors may enhance tolerance and further, reduce the interval between courses of chemotherapy.
Of note, some anti-tumor compounds have been developed with a weekly schedule. They include old drugs such as bleomycin, vincristine, methotrexate and 5-fluorouracil (5-FU), which tend not to give rise to myelotoxicity, or if so, only in a moderate form, but also, and more recently, drugs such as vinorelbine and gemcitabine, which are consistently myelotoxic.
Shortening the gap between chemotherapy cycles has been tried and developed for about 15 years in efforts to increase the 'dose-intensity' of cytotoxic agents. This concept has been actively developed in the clinic, because a dose-response curve has been demonstrated for many agents in vitro and in vivo in animal models. The dose-intensity of chemotherapy can be increased by higher drug doses, by reducing the time between cycles, or both. In the clinic, most investigators have focused on increasing dose-intensity by using massive doses of chemotherapy with bone marrow or peripheral stem-cell transplantation as consolidation therapy. This strategy, however, has not been translated into a gain in overall survival in the few solid tumors for which randomised studies are available [9, 10] . Some authors believe that rapidly-repeated high-dose chemotherapy would afford higher, more durable complete remissions than a singlecycle high-dose regimen given as consolidation [11] . Compared with this latter strategy, the theoretical advantages of a rapidly-repeated approach are 1) the early increase in dose-intensity proven decisive in some neoplasms [12] , 2) a decrease in mortality associated with the use of massive doses that has resisted attempts to obtain rates below 5% in many experiences, and 3) a decrease in the cost of treatment management, since hospitalization in a single isolated room is no longer required [13] . This is a review of the results reported recently with shortened intervals between courses of chemotherapy in solid tumors.
Methods
As recommended [14] , the literature was reviewed according to published methodology quality criteria. Mulrow's recommendations for reviewing medical articles were used [15] . These criteria include: purpose, data identification, data selection, validity assessment, qualitative synthesis, quantitative synthesis, summary, future directions.
Data identification
Data were obtained by the two investigators using the following procedures:
-a computer-assisted Medline search covering a 10-year period using the key words 'dose-intensity', 'dose-dense', 'densified' and 'chemotherapy'; -the Proceedings of the American Society of Clinical Oncology (ASCO) were hand-searched from 1993 to 1998 (6-year period) to identify dose-dense regimens; -the abstracts of the 1994, 1996 and 1998 issues of the European Society of Medical Oncology (ESMO) meetings were handsearched to identify dose-dense regimens, -the subject index of the Annals of Oncology, Cancer, European
Journal of Cancer, Journal of Clinical Oncology and Journal of the National Cancer Institute were systematically examined from the January 1993 through the December 1998 issues for the following key-words: 'dose-density', 'dose-intensity', 'highdose chemotherapy', 'chemotherapy'.
Data selection
Chemotherapy regimens recycled with intervals of less than three weeks were identified. Articles or abstracts reporting fewer than 20 patients were excluded from the analysis, except when rare neoplasms were the subject of the report Meeting abstracts, which did not result in a full publication during the three succeeding years, were not selected for analysis. In addition, reports on hematological malignancies were excluded and the review was sub-entitled 'A critical review of dose-dense chemotherapy in solid neoplasms'. The reports were classified according to the tumor type (e.g., breast cancer) and the remaining articles were grouped together in the chapter 'miscellaneous neoplasms'.
Validation assessment
The assessment of the data was standardized as follows: -randomized studies on dose-density were described extensively and were submitted to a critical analysis appearing first in each chapter; -phase II or feasibility studies were described more succinctly; -patient selection criteria were examined; -toxicity-related deaths were mentioned, when they were reported by authors; -the dose-intensity received or the relative dose-intensity were mentioned when reported.
Qualitative synthesis
We attempted to point out limitations and inconsistencies found in reports in each chapter.
Summary and future directions
Data are summarized in the abstract and in the conclusion. 
Results

Dose-density in small-cell lung cancer (SCLC)
A question that persists in oncology is whether a higher dose-intensity of chemotherapy can increase survival in SCLC [12, [16] [17] [18] [19] [20] [21] [22] [23] . Studies of dose-intensity in SCLC have produced conflicting results: some authors showed no correlation with survival, whereas others suggested that survival could potentially be improved by increasing dose-intensity. The major importance of high-dose cisplatin and cyclophosphamide during the first chemotherapy cycle has been demonstrated in a randomised trial [12] . To our knowledge, five randomised studies have compared dose-dense regimens to conventional chemotherapy [16] [17] [18] [19] [20] . Their results are summarised in Table 1 . First, European investigators reported that the adjunction of vindesine and cisplatin on day 8 and combination vincristine-methotrexate on day 15, to a three-drug combination (doxorubicin, cyclophosphamide and etoposide), repeated every three weeks had no effect on survival [16] . These disappointing results could have been due to the lower dose-intensity of the intensive regimen compared to that of the standard regimen, because of longer delays between courses in the former.
Furthermore, most toxicity-related deaths were observed in the intensive arm. Basically this regimen was not feasible because intervals were longer and the toxicityrelated death rate was high.
A second trial undertaken by a British team also compared a weekly to a three-weekly regimen. Patients did not receive prophylactic hematopoietic growth factors, nor had they in the previous trial. Results regarding dose-intensity are difficult to assess, as some drugs were used in only one of the two arms. No difference was detected in response nor in survival in this large study which included 438 patients [17] .
More recently, a third trial conducted by Europeans focused on reducing time intervals in the V-ICE regimen (ifosfamide, carboplatin, etoposide and vincristine) from four to three weeks by incorporating GM-CSF. Three hundred patients were enrolled and the final results were recently published [18] . They show that the three-week schedule allows an increase of 26% in dose-intensity received, compared to the four-week arm. This increase in dose-intensity yielded a significant improvement in survival (P = 0.0014) without increased toxicity. Twoyear survival was 33% and 18% in the intensive arm and the standard arm, respectively. This difference remained significant after adjustment for prognostic factors. Surprisingly, the complete response rate and median dura-tion of response were similar in the two arms and thus, the mechanism by which dose intensification conferred the survival benefit is unclear.
A Japanese randomised trial recently compared the weekly CODE schedule + G-CSF to the standard CAV/PE regimen [19) . Although the dose-intensity received in the weekly arm was twice that of the standard arm, there was no difference in complete response rates. The two-year survival rate was slightly better in the intensive arm but short of statistical significance (P = 0.10). However, the exclusion of patients with localized SCLC, the number of toxicity-related deaths and the fact that this trial was not powerful enough to detect a difference in survival of less than 15% could account for lack of a significant impact of the densification of chemotherapy on survival.
The latter randomised trial was recently reported by the MRC Lung Cancer Working Party [20] . Patients were randomised to receive six cycles of a doxorubicincyclophosphamide-etoposide combination, repeated fortnightly (with G-CSF) or three-weekly. Short intervals were respected mainly during the first cycles in the dose-dense arm. No difference between response rates was detected. Patients receiving the dose-dense arm obtained a significantly higher overall survival rate (P = 0.04). One-year survival was 47% in the intensive arm compared to 39% in the control arm. The final report from this study is pending. Among these five randomised studies, the three which increased the doseintensity by reducing the interval showed an improvement in survival (statistically significant in two).
There are continual debates as to whether dose-density, dose-intensity and survival of patients with SCLC might be increased by the use of hematopoietic growth factors. A survival benefit has been reported in some studies [18, 20, 22] but not in others [19, 21, 23, 24] when either G-CSF or GM-CSF were used to increase doseintensity. In the Japanese randomised trial that investigated whether the adjunction of G-CSF could improve the results of the CODE regimen, a survival benefit was reported [22] . However, this was a very small series and the survival of patients who received the standard CODE regimen was less than that originally reported with this schedule [25] . This signifies that the survival benefit reported with the CODE regimen combined with G-CSF by Fukuoka et al. may be artificial. Some authors claim that the beneficial effects of adding G-CSF to dose-dense regimens may be limited to regimens alternating hemato-toxic and non-hemato-toxic regimens [21, 22, 24] . Of note, a recent trial has shown that G-CSF administered up to 48 hours before the next chemotherapy course increases the risk of chemotherapyinduced neutropenia and thrombocytopenia [26] . The authors recommend increasing the window of time between the discontinuation of G-CSF and re-initiation of chemotherapy after the 48 hours in rapidly-repeated regimens.
Some phase II studies have also tested short-interval regimens in SCLC. These studies mainly report the clinical development of experimental schedules that are then used as investigational intensive arms in the abovecited phase III randomised studies. Murray et al. designed the CODE regimen, a weekly alternation of myelosuppressive and non-myelosuppressive treatments [25] . They reported an encouraging 30% two-year survival rate in selected extensive SCLC with acceptable toxicity. The CODE regimen was recently used as salvage therapy in 17 patients with relapsed SCLC and a median time off first-line chemotherapy of 6-7 months. An objective response was achieved in 15 of 17 (88%), and 5 were complete. No treatment-related deaths were observed [27] . Similarly, the Southwest Oncology Group (SWOG) has developed a weekly short-duration regimen with interesting results in limited-and extensive-stage SCLC [28] . Toxicity was acceptable and included one toxicity-related death in 76 patients. Investigators from the EORTC have attempted reducing intervals of the CDE regimen (cyclophosphamide, doxorubicin, etoposide) from three to two weeks with GM-CSF. They were able to increase the dose-intensity with GM-CSF only during the first courses [29] .
Dose-density in germ-cell tumors and trophoblastic gestational tumors
Although germ-cell tumors (GCT) are the most chemosensitive solid neoplasms, only one randomized study on dose-density has been reported to date [30] . Randomized trials focusing on dose-intensity have failed to show any benefit of double-dose cisplatin [31] or intensive chemotherapy with autologous bone marrow transplantation [9] in poor-risk patients. Investigators from the Medical Research Council (MRC) and the EORTC very recently reported the final results of a phase III trial comparing a rapidly-repeated intensive regimen (BOP/ VIP-B) to the standard 4 BEP in 380 patients with poorprognosis non-seminomatous GCT (NSGCT) [30] . The BOP/VIP-B regimen is a complex combination of bleomycin, vincristine, cisplatin, etoposide and ifosfamide (Table 2 ). This schedule was initially reported to be highly efficient in 91 patients treated in an uncontrolled study reported in 1991 [32] . Unfortunately, the intensive regimen in this randomised study afforded no complete responses nor any survival benefit. The higher number of toxicity-related deaths in the intensive arm (19 vs. 8) indicates that this regimen is in fact not readily feasible in a multicentre study. A higher proportion (10 vs. 5) of primary mediastinal NSGCT, notorious for their dismal outcome, in the intensive arm, is another plausible explanation for these negative results. A final explanation is that shortening cycles of chemotherapy may not enhance its effects in patients with germ-cell tumours. However, non-randomised trials testing dose-dense chemotherapy have yielded very promising results. These trials are summarised in Table 2 .
One of the oldest dose-dense schedules was the British POMB/ACE regimen [33] consisting of a complex combination of seven drugs, repeated alternatively at fortnightly intervals. Results obtained in 339 patients show that the three-year overall survival of patients with a poor prognosis according to the International GermCell Cancer Collaborative Group (IGCCCG) criteria [34] was 75%. This compares favorably with the 50% reported by the IGCCCG. However, the toxicity of this regimen has never been reported in detail and 1.4% of patients have died of its toxic effects.
In 1984, investigators from the University of Colorado reported the results of a weekly cisplatin-vincristinebleomycin regimen (BOP). Although the activity of single-agent vincristine in GCT is unknown, it was substituted for vinblastine in order 'to be able to give chemotherapy at much closer intervals'. Twenty-nine patients with advanced NSGCT were included and obtained a disease-free survival rate of 83%. The authors concluded that the BOP regimen was less toxic and as effective as the PVB combination [35] . However, these results are difficult to interpret because the number of patients is low and they were not classified according to prognosis. Subsequently, the BOP regimen was more often incorporated into alternating or sequential intensified regimens than used alone to treat advanced GCT. Dearnaley et al. reported the results of two cycles of a biweekly BOP regimen in a cohort of 116 patients with stage I NSGCT and at a high risk of relapse. The twoyear survival rate was 98%; toxicity was mild and compared favorably with that caused by the two cycles of BEP often used in this setting in Europe [36] . If these results are corroborated with a longer follow-up, two cycles of biweekly BOP should be considered a possible option in high-risk stage I NSGCT. Another accelerated induction regimen, the so-called C-BOP-BEP, was developed at the Royal Marsden Hospital [37, 38] . Courses are scheduled weekly (Table 2 ) but the results show that this interval could not be sustained. Toxicity was high with 7% of toxicity-related deaths. Again, survival results are very promising in the 41 poor-risk patients with a three-year OS of 91% (compared to 50% in the IGCCCG cohort). Surprisingly, results in the 27 intermediate-risk patients were more disappointing, as the three-year OS rate was only 68% (compared to 81% in the IGCCCG cohort). The excess number of toxicityrelated deaths may account in part for the mediocre results in this group. This regimen is now being evaluated in a phase II study by the EORTC.
The German Cooperative Group for Testicular Cancer has reported its experience with a rapidly alternating combination ( Table 2 ). The three-year disease-free survival and overall survival rates in poor-risk NSGCT according to this group's classification were, respectively, 61% and 76%. There were no deaths related to the intensive chemotherapy. However, two patients died of bleeding after resection of residual masses [39] . Similarly, investigators at the University of Barcelona have also reported results obtained with an intensive alternating multi-drug schedule, the so-called BOMP/EPI (Table 2) . No hematopoietic growth factors were given during this period. Twenty patients with high-risk NSGCT according to this institution's classification were treated with this regimen, and 18 of them (85%) remained disease-free over the long term. Their results were compared retrospectively with those obtained by the same investigators with the PVB regimen: there was a trend towards a better survival rate. Caution should be exercised when interpreting these results because the PVB regimen is no longer considered the standard therapy for high-risk GCT [41] , and secondly because a historical comparison may be biased. Investigators from the M.D. Anderson Cancer Center have also partially reported an interesting experience with dose-dense first-line chemotherapy in patients with poor-risk GCT. Combining the CISCA regimen developed at this institution, the British POMB/ACE and the BOP regimens, they used a dose-dense regimen in which courses were repeated every 7-14 days. Preliminary results of this phase II study show that this regimen is feasible without toxicity-related deaths. Strict recycling criteria were used : granulocyte count >1000/mm 3 , platelet count^ 50,000/mm 3 and grade 3-4 toxicity resolved. The preliminary results on response are promising (82% of complete responses after chemotherapy, with or without surgery) and the final results of this phase II study, including survival results, are now awaited [42] .
These regimens ought to be investigated in phase III randomized studies in order to determine whether they are truly superior to the standard four cycles of BEP in poor-risk patients. Moreover, the wide variation between these different reports in their definition of patients with poor-risk NSGCT precludes an adequate analysis of data. Bajorin et al. demonstrated that this type of bias may have a major impact on the results of a non-randomised trial [43] . IGCCCG criteria [34] should now be used worldwide to design prospective trials in poor-risk GCT.
The Memorial Group has developed a dose-dense and dose-intensive paclitaxel-based regimen for salvage strategies (Table 2 ) [44] . Preliminary results have been reported for 24 patients with a poor-risk relapse of GCT. Forty-six percent of them were alive and free of disease after a median follow-up of eleven months. A higher accrual is warranted but these results seem promising. Finally, a dose-dense intensive approach has proven capable of curing some patients who were highly pretreated with at least two previous lines of chemotherapy [45] . Using a complex combination of non-cross-resistant drugs recycled every week, Culine et al. obtained 8 of 14 complete responses; of these, 3 patients continue to be disease-free with an extended follow-up. This schedule is currently being investigated in a phase II multicenter French trial. Increasing the dose-intensity of cisplatin combined with sodium thiosulfate by shortening the interval between cycles has recently been validated [46] . Using a biweekly schedule, a dose of 180 mg/m 2 of cisplatin every two weeks was shown to be safe and feasible.
Two dose-dense regimens have been reported to obtain an 86% complete response rate in high-risk metastatic trophoblastic gestational tumors [47, 48] . The EMA/CO regimen is a combination of etoposide, methotrexate and actinomycin D alternated with cyclophosphamide and vincristine initially developed by Bagshawe [47] . When data from other centers were reviewed, a 73% complete remission rate was demonstrated in 104 patients [49] . As the combined activity of cyclophosphamide and vincristine was questionable in the EMA/CO regimen, investigators at the Institut Gustave-Roussy developed a biweekly combination of cisplatin, actinomycin D and etoposide (APE). The rationale for this regimen was also based on the wellknown activity of cisplatin in male choriocarcinoma. Preliminary results obtained in 19 patients showed an 86% complete response rate without life-threatening toxicity [48] . Definitive results are imminent. To date, a dose-dense chemotherapy regimen (EMA/CO or APE) is the current standard for poor-prognosis metastatic trophoblastic gestational tumor.
Dose-density in early breast cancer
Unlike those undertaken for advanced breast cancer, few randomized trials have evaluated the relevance of adjuvant or neo-adjuvant dose-dense regimens in early breast cancer. The feasibility of accelerated chemotherapy has been reported to be excellent in these patients [50] , Only one randomized trial performed by the Eastern Cooperative Oncology Group (ECOG) has been reported to date in the adjuvant setting [51] . This study included 646 patients with node-positive and hormone receptor-negative breast cancer. Patients randomized in the experimental arm were to receive a weekly regimen combining cyclophosphamide, 100 mg/m 2 /w for fluorouracil but were not increased for cyclophosphamide. It is still not clear whether such a modest increase in dose-intensity can contribute to these results, and endpoints other than dose-density, such as the effect of continuousinfusion fluorouracil or antimetabolite sequencing, have to be considered. No treatment-related deaths occurred in the 16-week arm versus three in the CAF arm (including one death due to congestive heart failure and two sepsis-related deaths). The quality of life of patients deteriorated significantly in the densified arm. Due to these facts, the authors do not recommend the 16-week regimen as a standard adjuvant treatment but their results warrant further investigations of densified schedules.
The results of a randomised trial of neoadjuvant therapy in locally advanced breast cancer have been reported very recently in abstract form [52] . This large trial merits special attention for it is one of the few comparing an optimal control arm, based on the most recent criteria, to a substantially densified arm. The primary endpoint of this study was progression-free survival but data on response rates or breast preservation were not presented in this meeting abstract. This study included 448 patients who were randomized to receive either 6 cycles of CEF (cyclophosphamide, epirubicin, 5-FU) repeated every 4 weeks or a combination of epirubicin, 120 mg/m 2 and cyclophosphamide, 830 mg/m 2 + G-CSF, repeated every 2 weeks, allowing an increase of 119% and 79% in the median dose-intensity for epirubicin and cyclophosphamide, respectively. Febrile neutropenia occurred in 14% of patients in the standard arm versus 8% in the densified arm, and a decrease in the left ventricular ejection fraction in 9% versus 12%. No toxicity-related deaths were reported. Unfortunately, with a median follow-up of 27 months, the progression-free survival is similar in the 2 treatment groups. Of note, the densified treatment results were tainted by a significantly lower quality of life score, but only during the first three months, and this score returned to baseline levels earlier in this group. Another smaller study (112 patients) comparing FAC repeated at 21-day versus 18-day intervals [53] showed significantly improved response rates at the expense of significantly increased toxicity (febrile neutropenia, mucositis, thrombocytopenia) without evidence of improved breast preservation rates. Moreover, the pathology-complete response rate was similar in both arms and there was no significant difference in disease-free survival at a very early stage of follow-up (Table 3) .
Results of biweekly adjuvant anthracycline-cyclophosphamide combinations have been reported in three prospective studies [54] [55] [56] which demonstrated excellent feasibility with a dose increment of 50%-100% [54] at the expense of significantly impaired quality of life [55] . With epirubicin at 75 mg/m 2 + cyclophosphamide 1200 mg/m 2 q 14 days, Cuvier et al. reported a 75%> twoyear disease-free survival rate in 59 patients with more than 5 involved nodes [56] .
The demonstrated efficacy of taxanes in metastatic breast cancer has motivated exploration of new rapidlyrepeated adjuvant combinations containing these drugs. Most of the experiences reported concern paclitaxel. The largest experience was reported by the Memorial Sloan Kettering Cancer Center [57] [58] [59] [60] which developed a sequential high-dose and biweekly-recycled combination of doxorubicin, paclitaxel and cyclophosphamide. The long-term distant disease-free survival yielded by these pilot studies published recently seems promising, with 81% after a median follow-up of 39 months in 42 patients with a median of 8 involved axillary nodes [60] . Data on doses and scheduling provided by these two trials [57, 60] were used to design a randomized study comparing the sequential biweekly-scheduled regimen to standard adjuvant chemotherapy which is ongoing.
Several pilot studies of locally advanced breast cancer patients treated with neo-adjuvant dose-densified chemotherapy have been published to date [61] [62] [63] [64] (Table 4) ; some of them included patients with advanced breast cancer and will be detailed further on. In summary, pathology-complete response rates were not enhanced in three series [61, 63, 64] . Moreover, evidence of better breast preservation rates is still lacking -32% [64] to 80% [61] . In inflammatory breast cancer, a single study of 48 patients who received a biweekly combination of epirubicin at 75 mg/m 2 and cyclophosphamide, 1200 mg/m 2 , without G-CSF [6] obtained a four-year overall survival rate of 66% which compares very favourably with literature data. The planned dose intensity was admirably attained with dose intensities of 102% and 97% at the fourth and sixth cycles, respectively. These particular subgroups of rapidly growing malignancies may represent a good indication for densified schedules. A randomized study is the sole means of demonstrating the superiority of dose-dense regimens but in view of the rarity of this entity, such a study would be difficult to complete.
In summary, with three negative randomized trials published to date, evidence is still lacking as to whether adjuvant or neo-adjuvant densified regimens have an edge over optimal standard anthracycline-based regimens. Moreover, although feasibility is excellent, dosedensity does exert a detrimental effect on the quality of life reported in two of these trials. This is essentially why densified-regimens cannot be recommended as a standard adjuvant or neo-adjuvant therapy. Two points need, however, to be underlined and warrant further investigations: firstly, a trend towards improved progression-free survival is reported in the only randomized study on adjuvant therapy [51] . This must be appreciated in the light of the encouraging results reported in pilot studies including patients with massive axillary involvement [56, 60] . Secondly, breast preservation was the endpoint addressed for locally advanced breast cancer only in a single randomized study and the impressive local control rates achieved in some small pilot studies [61, 62, 64 ] have yet to be confirmed.
Dose-density in metastatic breast cancer
An entire body of randomised trials evaluating dosedensified chemotherapy are now officially available on metastatic breast cancer. Biganzoli and Piccart undertook a review of these results in a recent issue of Annals of Oncology [65] . Most of the studies, however, compared standard anthracycline-based regimens repeated every three weeks with a reduced dose per course and shortened cycle intervals [66] [67] [68] 74] and failed to demonstrate a significant benefit with accelerated chemotherapy (Table 3) . Of special interest is the study by Blomqvist et al. in which the relative dose-intensity was similar in both arms [68] . The response and survival rates obtained in the accelerated chemotherapy group was significantly below those of the standard FEC arm. The population included in this trial was surprisingly low for the rate of measurable disease but it may indeed be an accurate reflection of the general population of patients with metastatic breast cancer, (avoiding some of the selection biases commonly present in phase II studies). These results strongly support the hypothesis of an efficiency threshold per cycle, regardless of dose intensity. Three other trials [66, 67, 74] compared doxorubicin weekly versus every 21 days at a similar dose-intensity in each arm and failed to show any benefit with the weekly schedule. The aim of the most recent trial [74] was to compare a weekly single-agent versus combination chemotherapy repeated every three weeks: with standard FEC every 21 days, a trend was noted towards a longer duration of response (12 versus 10.5 months; P -0.07) whereas overall survival was not significantly different.
Only two studies have compared standard and reduced cycle intervals with a constant dose per course and conventional anthracycline-based regimens [69, 70] . Ardizzoni et al. [69] randomized FEC every 21 days versus FEC every 14 days: an increase of approximately 30% in dose intensity was achieved without life-threatening toxicity. Results, however, remained disappointing and the upgraded objective response and disease-free survival rates did not reach statistical significance. The second study was a three-arm randomisation between standard FNC (5-FU, mitoxantrone, cyclophosphamide) every 21 days versus every 14 days versus escalated FNC every 21 days. Results are far too preliminary for definitive conclusions [70] . Past experience with dose-escalation in metastatic breast cancer provides firm evidence that increasing dose intensity by a factor of 1.5-2 does not necessarily improve treatment results [71] . The probability of obtaining a major benefit is very slim if cycle intervals are simply reduced without increasing the dose per course. Associating reduced intervals with moderate dose increments is, however, a more effective and safer way of increasing dose intensity than dose escalation alone. Incidentally, investigators from the Netherlands have shown that the interval between cycles can be reduced safely to 10 days, allowing better dose-intensity with less toxicity, compared to a three-week schedule with dose escalation [72] ,
The only study that randomised biweekly versus monthly high-dose anthracyclines failed to show any survival benefit with dose-densified chemotherapy despite an improvement in the complete response rate [73] . The median dose intensity of epirubicin was doubled (27.2 versus 52.9 mg/m 2 /w) but there was no significant difference in the incidence of grade 3-4 toxicity between the two groups. Data from the literature show that complete response is highly correlated with prolonged survival [75] ; the survival benefit in this study may therefore be restricted to this subgroup of patients and remains undetermined because of the limited number of patients. It is also noteworthy that this study used a single agent rather than a conventional combination.
In summary, the randomised trials conducted in metastatic breast cancer do not report any major benefit from dose-densified chemotherapy (Table 3) . Moreover, accelerated chemotherapy with reduced doses per cycle is probably detrimental and should no longer be recommended. However, the improved complete response rates and the trend toward better objective response rates and survival observed in two studies [69, 73] appears to support the hypothesis that dose-densified chemotherapy may be useful in a selected subgroup of patients. Further investigations are therefore warranted in selected subgroups.
Many pilot studies of dose-dense chemotherapy in metastatic breast cancer have become available since the small series reported by Bronchud et al. in 1984 [76] and are summarized in Table 4 [6, [61] [62] [63] [64] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] . The safety and feasibility of densified anthracycline-cyclophosphamide combinations have been demonstrated and the toxicity reported in these studies, especially regarding neutropenic fever or congestive heart failure, is not greater than that observed with anthracycline-based regimens repeated every 21 days. Moreover, a large number of these studies [77] [78] [79] [80] reported response or survival rates which compare very favourably with those in the literature. More recent studies have used weekly taxanes whose tolerance profile is acceptable, with no severe hematologic or neurologic toxicities [83] [84] [85] [86] [87] [88] [89] [90] . Several of them, however, mixed locally advanced and metastatic disease and sometimes other cancers such as ovarian carcinomas [86] and thus obviate firm conclusions. Weekly administration appears to be a safe method of dose-intensity expansion with taxanes, whose efficiency must now be evaluated in larger trials.
Dose-density in the Ewing's sarcoma family of tumors
Ewing's sarcoma and peripheral primitive neuroectodermal tumors share common clinical and biological features and have been designated the Ewing family of tumors [106] . In unselected patient populations, fiveyear overall survival is about 55% when disease is localized and less than 10% in patients with metastasis at diagnosis. A few attempts have recently been made to increase these rates using dose-dense regimens. No randomized study has compared a dose-dense regimen to a standard regimen, because these neoplasms are rare.
However, data reported to date with the use of dosedense regimens are encouraging. Kushner et al. have developed the P6 protocol at the Memorial SloanKettering Cancer Center, a rapidly-repeated regimen combining doxorubicin, vincristine and high-dose cyclophosphamide (HD-DAV) and ifosfamide-etoposide regimen [107] . Courses were started once neutrophil and platelet counts had reached 500/ul and 100,000/ul, respectively. An excellent two-year event-free survival rate of 77% was obtained in patients with localized disease and adverse prognostic factors at presentation (tumor volume > 100 cm ). The regimen was shown to be feasible in a short period of time and most patients received the first three courses of chemotherapy within seven weeks. Toxicity was severe and included myelosuppression (one toxicity-related death), mucositis and peripheral neuropathy. Similar encouraging results were obtained in patients with desmoplastic small round-cell tumors (DSRCT), a treatment-resistant cancer, with 5 of 10 disease-free survivors after a follow-up of about 1 year [108] . However, further follow-up is necessary for firm conclusions as to whether successful results of the P6 regimen will improve the cure rates of patients with Ewing's sarcoma and DSRCT.
Another dose-dense strategy was developed at the Institut Gustave-Roussy. Patients with neoplasms of the Ewing's sarcoma family received two induction courses of doxorubicin, cisplatin and ifosfamide followed by the same regimen without cisplatin on day 15. Each course was repeated every four weeks with G-CSF support. Preliminary results have been reported and show that 15 of 16 patients, with localized disease and an axial primary or a bulky tumor in 14 of them, were rendered disease-free after a median follow-up of 24 months at this point in time. A mean interval of 15.7 days between cycles was reported [108] . These results compare favorably with the 77% two-year overall survival reported in a cohort of adults with localized Ewing's sarcoma, including those whose lesions were not axial or bulky primaries [110] .
Dose-density in colorectal carcinoma
In colorectal cancer, dose-densified chemotherapy has been used extensively. As hematological toxicity is limited, weekly or biweekly administration of 5-FU has been used since the 1980s. In 1994, Buroker et al. reported the results of a randomized study comparing weekly 5-FU plus high-dose leucovorin to the classic monthly Mayo clinic regimen. A non-significant trend towards a benefit was found in progression-free survival. However, the difference between treatments remained non-significant after adjustment with prognostic factors. The monthly regimen was reported to be associated with a lower financial cost and manageable toxicity with less need for hospitalization [111] . More recently, French investigators have compared a bimonthly high-dose leucovorin and fluorouracil bolus plus a continuous infusion regimen to the Mayo clinic regimen [112] . The De Gramont regimen (LV5-FU2) combines leucovorin 200 mg/m 2 , bolus 5-FU 400 mg/m 2 and 5-FU 600 mg/m 2 as a 24-hour infusion given on two consecutive days and repeated every two weeks. This regimen has proven effective, yielding an objective response rate of 32.6%, a median progression-free survival duration of 28 weeks and a median survival of 62 weeks. The figures for the monthly regimen were, respectively, 14.4%, 22 weeks and 57 weeks. The difference was significant for the response rate (P = 0.0004) and progression-free survival (P -0.0012) and of borderline significance for survival (P -0.07). Moreover, the bimonthly regimen was less toxic than the monthly regimen. Very recently, a randomized German trial suggested that patients with metastatic colorectal cancer receiving an intensive regimen could expect a significantly better survival. To date, the results of this trial have been reported only in abstract form [113] . Patients were randomly assigned to receive either weekly folinic acid, 500 mg/m 2 , followed by 5-FU, 2600 mg/m 2 as a 24-hour infusion, with a twoweek free interval after one month of therapy, or a standard Mayo Clinic regimen, repeated every month. This trial included 149 patients with untreated metastatic colorectal cancer. Arms were well-balanced with respect to prognostic factors. The median survival is 463 days in the intensive arm compared to 370 days in the standard arm. Of note, the median survival of the patients recruited in the standard arm is roughly the same as that usually reported in unpretreated colorectal cancer patients. The difference between curves was statistically significant. However the P-value was not reported. This difference was probably associated with a significantly smaller number of patients with early disease progression (19% and 48%, respectively).
Many non-randomized trials using weekly or bi-weekly 5-FU have been reported, mostly in abstract form. To date, many European investigators consider dose-dense 5-FU-based regimens as standard therapy in advanced colorectal cancer. This is why such regimens have been combined with new active drugs, mainly oxaliplatin and irinotecan. The experience with regimens combining 5-FU, leucovorin and oxaliplatin has recently been reviewed extensively [114] . De Gramont has reported a small but significant benefit in time to progression with the adjunction of bi-weekly oxaliplatin to the LV5-FU2 regimen [115] . Currently, various new combinations of bi-weekly oxaliplatin, 5-FU or CPT11 are under study in phase I and II trials [114] . Whether the three-drug combination of thymidilate synthase inhibitors (mainly 5-FU and Tomudex), oxaliplatin and CPT11 recycled bi-weekly will be feasible and more effective than the two-drug combinations will be a new challenge for oncologists. Furthermore, we are now awaiting the results of dose-dense regimens in adjuvant colorectal cancer patients.
Dose-density in gastric carcinoma
At the end of the 1980s, the majority of investigators considered 5-FU alone or in combination with doxorubicin and mitomycin (FAM) to be standard therapy for advanced gastric cancer. The sequential combination of high-dose methotrexate and 5-FU alternated every two weeks with doxorubicin (FAMTX) was shown to yield encouraging results in phase II trials. Based on these data, a randomized study comparing FAMTX to FAM was performed by the EORTC and showed a significantly better response rate and overall survival (41% versus 22% at one year, respectively, P = 0.004) for the dose-dense FAMTX regimen [116] . Subsequently, FAMTX was compared to the etoposide, doxorubicin and cisplatin (EAP) combination given on days 1-8, repeated every four weeks [117] . No significant difference in survival was detected between the two regimens and the toxicities of FAMTX were found to be more manageable. Thus, FAMTX became standard therapy for several years in advanced gastric cancer. Recently, however, investigators from the Royal Marsden Hospital reported a better response rate, quality of life and survival with continuous 5-FU, epirubicin and cisplatin, repeated every three weeks (ECF), compared to the FAMTX regimen: 36% and 21% at one year, respectively (P = 0.00006) in a randomized study [118] . The high level of dose-intensity obtained using protracted 5-FU in the ECF regimen might explain these better results. Finally, Italian investigators very recently reported encouraging results of a phase II study of a complex weekly regimen combining fluorouracil, cisplatin, epirubicin, leucovorin, glutathione and G-CSF [119] . In this trial, a response rate of 62% and a median survival of 11 months were obtained in 105 patients. The promising results of this dose-dense regimen will have to be confirmed in a randomized trial comparing it to the ECF regimen before the former can be considered the standard therapy.
Dose-density in urothelial carcinoma
The M-VAC regimen has been considered the gold standard for advanced transitional cell carcinoma of the urinary tract since the 1980s. Despite extensive use of hematopoietic growth factors, enhancing tolerance to chemotherapy in some trials, no significantly improved response rates or survival have been reported to date. In a study reported by a team from the M.D. Anderson, 48 patients were randomized to receive a modified M-VAC schedule with or without GM-CSF [120] . Chemotherapy was repeated every 23 days or when biological criteria were met. The results show no difference in the dose intensity, response rate or survival. However, this trial was not designed to detect a difference in response or survival. A second randomized trial conducted by the EORTC has compared the classic M-VAC regimen to a biweekly M-VAC + G-CSF. Accrual to this trial was recently discontinued. An interim toxicity analysis was presented in 1997: a lower incidence of febrile neutropenia, a greater dose-intensity for doxorubicin and cisplatin and better treatment compliance were reported for the dose-dense arm [121] . Data on response and survival are now awaited.
Several non-randomized trials have tried to reduce the intervals in the M-VAC regimen [122] [123] [124] . Investigators at the Memorial Sloan-Kettering Cancer Center initiated a phase I study in 23 patients, to evaluate the maximum tolerable dose of M-VAC with G-CSF support and to define the best interval between cycles (two or three weeks). They found that the dose-intensity of M-VAC could be escalated by 33% using a threeweekly schedule. However, this dose-intensity was maintained through the first three cycles only [122] . A Japanese trial has also demonstrated that the interval between cycles of the M-VAC regimen could be safely reduced from three weeks to four weeks with G-CSF support. In this study, the duration of the hospital stay was reduced by two weeks in patients receiving the dosedense M-VAC [123] . During roughly the same period, the Eastern Cooperative Oncology Group reported disappointing results and a significant toxicity with a fourweekly regimen of intensified M-VAC + G-CSF [124] . Thus, reducing the time interval of the M-VAC regimen from four to three weeks seems feasible and may slightly enhance the dose intensity. However, the toxicity of standard M-VAC and the poor tolerance documented in patients with advanced urothelial carcinomas makes it unlikely that patient outcome will be significantly improved.
Dose-density in miscellaneous tumors
To our knowledge, only anecdotal studies of dose-densified chemotherapy in other solid neoplasms have been published and these mainly concern head and neck carcinomas, gynecologic cancers and soft-tissue sarcomas. No definitive results are available from randomized studies for these neoplasms. The feasibility of dosedense chemotherapy was the focus of the series devoted to these neoplasms, but the limited size of the patient populations precludes any definitive conclusions.
In head and neck carcinomas, a biweekly 5-FU + cisplatinum schedule yielded an encouraging 82% response rate in a heterogeneous series of 44 patients [125] . Similar results were reported with cisplatin, 100 mg/m 2 on days 1 and 8 followed by local irradiation in those patients with locally advanced disease [126] . Of particular interest is the study reported by Verweij et al., 59 patients with locally advanced head and neck carcinoma were given six cycles of weekly cisplatin (80 mg/m 2 ) before local therapy. Non-hematologic toxicities were manageable. However, the incidence of severe leukopenia and/or thrombocytopenia was high (17 patients with each toxicity) and only nine patients received the planned dose intensity. Moreover, auditive toxicity was noted in 13 patients. The authors concluded that dose-densified cisplatin as a single agent compares favourably with classic combinations in head and neck carcinomas [127] .
A single report has been published on a weekly schedule of adjuvant and neo-adjuvant vincristine-bleomycin-methotrexate in 38 patients with nodal metastases from penile carcinomas. Toxicity was moderate but this regimen seems less effective than conventional 5-FU-cisplatin combinations in patients with unresectable metastases [128] . In metastatic adenocarcinoma of the cervix, weekly epirubicin is well-tolerated but of minimal activity [129] . A moderate increase in doseintensity has been achieved in adult soft-tissue sarcomas, while shortening cycle intervals with an EID regime, but its clinical implications remain unproven [130] . In mesothelioma, promising results had initially been reported with the combination of weekly cisplatin and oc-interferon or with weekly cisplatin alone [131, 132] but were not confirmed later [133] . Moreover, the toxicity/efficacy ratio of this strategy compares poorly with that of more recent chemotherapy combinations [134] .
Conclusions
Considerable experience has been accumulated in rapidly-repeated regimens, as summarised in this review. Results clearly indicate that this strategy is feasible in many oncologic settings, with manageable toxicity and a limited number of toxicity-related deaths, when therapy is adequately monitored by well-trained oncologists. Response rates are impressive in a number of neoplasms, and particularly in the case of germ-cell tumours, breast cancer, ovarian cancer, Ewing's sarcoma and colorectal cancer. To date, only a few randomized trials have demonstrated a benefit in disease-free survival or overall survival in small-cell lung cancer and advanced colorectal cancer [18, 20, 112, 113] . Such a benefit is suggested in other uncontrolled studies in various neoplasms, and especially germ-cell tumors, gestational trophoblastic disease, Ewing's sarcoma and perhaps high-risk node-positive breast cancer [33, 38, 42, 47, 48, 57-60, 107, 109] . In parallel, a better efficacy/ toxicity ratio has been reported in some models with sequential chemotherapy as compared to alternated or concurrent schedules [5] . This indicates that investigators should now focus research on rapidly-repeated sequential schedules.
However, 'one cycle every three or four weeks' is certainly not definitively obsolete, even if many biological and clinical arguments are strongly in favour of rapidly-repeated regimens. Although the activity of dosedense chemotherapy is potentially superior to that of standard treatments in some solid tumours, the clinical impact of this benefit is likely to be limited and should be weighed against quality of life impairment that may be associated with more toxic dose-dense regimens. Moreover, clinical and biological criteria earmarking candidate patient subgroups likely to benefit from this strategy are not available. Combining dose-dense chemotherapy regimens with new anti-cancer strategies in light of insights into the mechanisms of oncogenesis will be a challenge on the eve of the millenium. It is noteworthy that most randomized studies which suggested a benefit with dose-dense chemotherapy also reported increased dose-intensity in the experimental arm. If such is the case, shortening cycle intervals would probably be one of the most efficient ways of increasing dose intensity, as previously suggested [72] . This brings to the fore the concept of dose-intensity measurement which has been a subject of controversy since the measurement standard (mg/m /week) was recently criticised by Gurney et al. [135, 136] : the issue addressed by these authors, which is of major import in the practice of medical oncology, could be summarised thus: 'Prescribing anticancer agents in mg/m 2 , is it obsolete?' They showed that there is no or only a limited correlation between the body surface area and pharmacokinetic parameters for most drugs. The body surface area proved to be an inadequate yardstick for standardising marked inter-patient variation in pharmacokinetics and this appeared relevant for most cytotoxic agents [135] [136] [137] [138] [139] . This could partially account for some of the shortcomings of many current dose-intensity strategies.
